Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Blood 1,25-dihydroxycholecalciferol increased

Source: 3.3. Top 30 ADE signals for Denosumab. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

Study design awaiting verification · PLOS One · 2026

Original publication title

Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

Shaohuan Lu; Dongxiao Wang; Caiming Xiong; Jialing Liang; Yang Li; Canhua Liang; Qianxi Chen; Guangyi Meng

© 2026 Lu et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To detect and quantify adverse drug event (ADE) signals linked to 120 mg denosumab in the real world.

Source: Objective

Abstract: What methods does the paper describe?

We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) for reports on 120 mg denosumab, standardized, and categorized these events with Preferred Terms (PT) and System Organ Classes (SOC) from MedDRA version 27.1. Disproportionality analysis was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN).

Source: Methods

Abstract: Results

We identified 10,963 ADE reports for 120 mg of denosumab. Among 10 963 reports, 41.6% of patients were ≥ 65 years old, 37.1% were from the United States, and 17.7% were from Japan; 77.0% were serious. Data mining revealed 294 positive disproportionality signals across 27 SOCs. The highest signal proportions were for neoplasms (15.99%), musculoskeletal disorders (13.27%), infections (11.56%), gastrointestinal disorders (10.88%), and procedural complications (10.20%). The most frequent ADEs were osteonecrosis of the jaw (n = 3,082, 28.11%), death (n = 803, 7.32%), hypocalcemia (n = 799, 7.29%), and fatigue (n = 282, 2.57%).

The strongest signals by ROR were bone giant cell tumor (7888.08), bone giant cell tumor malignant (6502.96), osteonecrosis of the jaw (396.57), and bone giant cell tumor benign (312.37). Thirty-two unlisted events were identified, including exostosis of jaw, osteosarcoma, tooth fracture, and bone lesions.

Source: Results

Abstract: Conclusions

Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes.

Source: Conclusions
Authors’ abstract

Objective

To detect and quantify adverse drug event (ADE) signals linked to 120 mg denosumab in the real world.

Methods

We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) for reports on 120 mg denosumab, standardized, and categorized these events with Preferred Terms (PT) and System Organ Classes (SOC) from MedDRA version 27.1. Disproportionality analysis was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN).

Results

We identified 10,963 ADE reports for 120 mg of denosumab. Among 10 963 reports, 41.6% of patients were ≥ 65 years old, 37.1% were from the United States, and 17.7% were from Japan; 77.0% were serious. Data mining revealed 294 positive disproportionality signals across 27 SOCs. The highest signal proportions were for neoplasms (15.99%), musculoskeletal disorders (13.27%), infections (11.56%), gastrointestinal disorders (10.88%), and procedural complications (10.20%). The most frequent ADEs were osteonecrosis of the jaw (n = 3,082, 28.11%), death (n = 803, 7.32%), hypocalcemia (n = 799, 7.29%), and fatigue (n = 282, 2.57%).

The strongest signals by ROR were bone giant cell tumor (7888.08), bone giant cell tumor malignant (6502.96), osteonecrosis of the jaw (396.57), and bone giant cell tumor benign (312.37). Thirty-two unlisted events were identified, including exostosis of jaw, osteosarcoma, tooth fracture, and bone lesions.

Conclusions

Clinicians should maintain vigilance for both established toxicities and these 32 emerging signals to ensure the safety of patients receiving 120 mg of denosumab for oncological purposes.

Publication and source details

Original title: Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice

Shaohuan Lu; Dongxiao Wang; Caiming Xiong; Jialing Liang; Yang Li; Canhua Liang; Qianxi Chen; Guangyi Meng

PLOS One · 2026

* E-mail: wonderfulqx@163.com (QXC), ylsymgy@163.com (GYM)

Competing Interests: The authors declare no competing Interests.

© 2026 Lu et al2026Lu et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Bethune Charitable Foundation 2024 'Radiant China' Pharmaceutical Research Capacity Building Grant YLSY-ZH-QT-202410(019) https://orcid.org/0009-0007-3240-5191 Meng Guangyi Guangxi Science and Technology Major Project GuikeAA22096030 Chen Qianxi Bethune Charitable Foundation 2024 ‘Radiant China’ Pharmaceutical Research Capacity Building Grant (No. YLSY-ZH-QT-202410(019)) Guangyi Meng 50 000 RMB https://www.bqejjh.org.cn/ Guangxi Science and Technology Major Project (GuikeAA22096030) Qianxi Chen 4 800 000 RMB http://kjt.gxzf.gov.cn/ There was no additional external funding received for this study.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:12:26.585032+00:00

DOI: 10.1371/journal.pone.0342188 · PMC12863689